Myriad Genetics, Inc. (NASDAQ:MYGN) is set to announce its earnings results after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of $0.21 per share for the quarter. Myriad Genetics has set its Q1 guidance at $0.19-0.21 EPS and its FY18 guidance at $1.00-1.05 EPS.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.04. Myriad Genetics had a return on equity of 9.67% and a net margin of 2.83%. The firm had revenue of $200.50 million during the quarter, compared to the consensus estimate of $193.71 million. During the same period last year, the business posted $0.36 EPS. Myriad Genetics’s quarterly revenue was up 7.5% on a year-over-year basis. On average, analysts expect Myriad Genetics to post $1.04 EPS for the current fiscal year and $1.19 EPS for the next fiscal year.

Myriad Genetics, Inc. (NASDAQ:MYGN) traded up 0.073% during trading on Tuesday, reaching $34.475. The company had a trading volume of 367,439 shares. The company has a 50-day moving average of $34.87 and a 200-day moving average of $26.93. The firm has a market capitalization of $2.36 billion, a P/E ratio of 108.072 and a beta of 0.27. Myriad Genetics, Inc. has a 52-week low of $15.15 and a 52-week high of $37.30.

In other Myriad Genetics news, Director John T. Henderson sold 30,000 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $30.30, for a total transaction of $909,000.00. Following the sale, the director now directly owns 52,524 shares of the company’s stock, valued at approximately $1,591,477.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 6.70% of the stock is owned by insiders.

Several brokerages recently commented on MYGN. Cowen and Company reissued a “hold” rating and set a $25.00 target price on shares of Myriad Genetics in a report on Sunday, September 17th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $23.00 price target (up previously from $21.00) on shares of Myriad Genetics in a report on Thursday, August 10th. BidaskClub cut Myriad Genetics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Zacks Investment Research raised Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a report on Monday, July 17th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and issued a $22.00 price target on shares of Myriad Genetics in a report on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $26.40.

TRADEMARK VIOLATION NOTICE: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Earnings History for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with's FREE daily email newsletter.